Experiments were carried out to test the efficacy and safety of the heparin removal device, a plasmapheresis filter that binds and eliminates heparin, in the context of extracorporeal circulation.
Procedures and Findings
Six dogs were put on cardiopulmonary bypass after heparinization. Upon weaning, additional heparin was administered to obtain an activated clotting time above 900s. The animals were connected to the heparin removal device and with flows of 500 ml/min, activated clotting time, activated partial thromboplastin time and plasma heparin concentrations were normalised to baseline after 30 min. Hemodynamic parameters remained unaffected. A slight decrease in red and white blood cell count and in platelets was observed which however recovered spontaneously two hours after the filter procedure. No damage to blood components could be observed.
Conclusions
The use of a heparin removal device is as efficient as systemic administration of protamine to reverse the effects of heparinization. It may prevent the adverse reactions linked to protamine administration and therefore be indicated in certain subgroups of patients undergoing cardiopulmonary bypass.
LindbladB.Protamine sulphate: a review of its effects: hypersensitivity and toxicity. Eur J Vasc Surg1989; 3: 195–201.
4.
WakefieldT.W., HantlerC.B., LindbladB., WhitehouseWMJr., StanleyJ.C.Protamine pretreatment attenuation of hemodynamic and hematologic effects of heparin-protamine interaction. J Vasc Surg1986; 3: 885–9.
5.
MorelD.R., LowensteinE., NguyenduyT.Acute pulmonary vasoconstriction and thromboxane release during protamine reversal of heparin anticoagulation in awake sheep: evidence for the role of reactive oxygen metabolites following nonimmunological complement activation. Circ Res1988; 62: 905–15.
6.
WeilerJ.M., FreimanP., SharathM.D.Serious adverse reactions to protamine sulphate: are alternatives needed?J Allergy Clin Immunol1985; 75: 297–303.
7.
YangV.C., PortF.K., KimJ-S, TengC-L, TillG.O., WakefieldT.W.The use of immobilised protamine in removing heparin and preventing protamine-induced complications during extracorporeal blood circulation. Anesthesiology1991; 75: 288–97.
MaX., MohammadS.F., KimS.W.Interaction of heparin with polyallylamine-immobilised surfaces. J Biomed Mat Res1993; 27: 357–65.
10.
ArnoldL.J., DaganL.J., GutheilJ., KaplanN.O.Antineoplastic activity of poly-L-lysine with some ascites tumor cells. Proc Natl Acad Sci USA1979; 76: 3246–50.
11.
CranneyJ., PoulsenS., McReaJ., TrioloP., SchwartzE.Three week toxicity study of a heparin removal device in dogs. Poster. 19th Annual Meeting of the Society for Biomaterials in conjunction with the 25th International Biomaterials Symposium. April 28 - May 2 1993, Birmingham, AL.
12.
FabianI., AronsonM.Polycations as possible substitutes for protamine in heparin neutralization. Thromb Research1980; 17: 239–47.
13.
MaX., MohammadS.F., KimS.W.Heparin removal from blood using poly(L-lysine) immobilised hollow fiber. Biotech Bioeng1992; 40: 530–6.
14.
HorrowJ.C.Protamine: a review of its toxicity. Anesth Analg1985; 64: 348–61.
15.
ConahanTJIII, AndrewsR.W., MacVaughHIII. Cardiovascular effects of protamine sulphate in man. Anesth Analg1981; 60: 33–6.
16.
JaquesL.B.Protamine: antagonist to heparin. Can Med Assoc J1973; 108: 1291–7.
17.
KirklinJ.K., ChenowethD.E., NaftelD.C.Effects of protamine administration after cardiopulmonary bypass on complement, blood elements, and the hemodynamic state. Ann Thorac Surg1986; 41: 193–9.
18.
MorelD.R., CostabellaP.M.M., PittetJ.F.Adverse cardiopulmonary effects and increased plasma thromboxane concentrations following the neutralisation of heparin with protamine in awake sheep are infusion-rate dependent. Anesthesiology1990; 73: 415–24.
19.
DeggesR.D., FosterM.E., DangA.Q., ReadR.C.Pulmonary hypertensive effect of heparin and protamine interaction: evidence for thromboxane B2 release from the lung. Am J Surg1987; 154: 696–9.
HammersmidtD.E., StrocekD.F., BowersT.K.Complement activation and neutropenia occurring during cardiopulmonary bypass. J Thorac Cardiovasc Surg1981; 81: 370–7.
29.
KirschfinkM., KovacsB., MottaghyK.Extracorporeal circulation: in vivo and in vitro analysis of complement activation by heparin-bonded surfaces. Circulatory Shock1993; 40: 221–6.
30.
ReutR., ErtelN., EiensteinR., GewurzH.Complement activation by interaction of polyanions and polycations: heparin-protamine induced consumption of complement. J Immunol1975; 114: 120–4.
31.
FiedelB.A., ReutR., MyhrmanR., GewurzH.Complement activation by interaction of polyanions and polycations: II. precipitation and the role of IgG, C1q and C1-INH during heparin-protamine induced consumption of complement. Immunology1976; 30: 161–9.
32.
WeilerJ.M., GellhausM.A., CarterJ.G.A prospective study of the risk of an immediate adverse reaction to protamine sulphate during cardiopulmonary bypass surgery. J Allergy Clin Immunol1990; 58: 713–9.
33.
WeissM.E., NyhanD., PengZ.Association of protamine IgG and IgG antibodies with life-threatening reactions to intravenous protamine. N Engl J Med1989; 320: 886–92.
34.
LakinJ.D., BlockerT.J., StrongD.M., YocumM.W.Anaphylaxis to protamine sulphate mediated by a complement derived IgG antibody. J Allergy Clin Immunol1978; 61: 102–7.
